HomeCompareSURGW vs MRK

SURGW vs MRK: Dividend Comparison 2026

SURGW yields 22988.51% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SURGW wins by $209253913157569118208.00M in total portfolio value
10 years
SURGW
SURGW
● Live price
22988.51%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$209253913157569118208.00M
Annual income
$207,478,497,165,779,060,000,000,000.00
Full SURGW calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — SURGW vs MRK

📍 SURGW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSURGWMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SURGW + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SURGW pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SURGW
Annual income on $10K today (after 15% tax)
$1,954,022.99/yr
After 10yr DRIP, annual income (after tax)
$176,356,722,590,912,200,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, SURGW beats the other by $176,356,722,590,912,200,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SURGW + MRK for your $10,000?

SURGW: 50%MRK: 50%
100% MRK50/50100% SURGW
Portfolio after 10yr
$104626956578784559104.00M
Annual income
$103,739,248,582,889,530,000,000,000.00/yr
Blended yield
99.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

SURGW
No analyst data
Altman Z
-14.7
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SURGW buys
0
MRK buys
0
No recent congressional trades found for SURGW or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSURGWMRK
Forward yield22988.51%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$209253913157569118208.00M$56.8K
Annual income after 10y$207,478,497,165,779,060,000,000,000.00$9,798.13
Total dividends collected$209136897216972292096.00M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SURGW vs MRK ($10,000, DRIP)

YearSURGW PortfolioSURGW Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$2,309,551$2,298,850.57$11,206$366.19+$2.30MSURGW
2$498,668,571$496,197,351.96$12,650$502.35+$498.66MSURGW
3$100,661,493,199$100,127,917,828.11$14,407$694.19+$100661.48MSURGW
4$18,997,308,529,480$18,889,600,731,757.26$16,585$967.82+$18997308.51MSURGW
5$3,352,041,078,501,299$3,331,713,958,374,754.50$19,342$1,363.89+$3352041078.48MSURGW
6$553,002,537,294,905,860$549,415,853,340,909,500.00$22,913$1,947.19+$553002537294.88MSURGW
7$85,301,813,974,046,130,000$84,710,101,259,140,560,000.00$27,662$2,823.89+$85301813974046.09MSURGW
8$12,303,154,006,383,179,000,000$12,211,881,065,430,949,000,000.00$34,159$4,173.35+$12303154006383178.00MSURGW
9$1,659,267,282,046,792,600,000,000$1,646,102,907,259,962,700,000,000.00$43,337$6,308.80+$1659267282046792704.00MSURGW
10$209,253,913,157,569,130,000,000,000$207,478,497,165,779,060,000,000,000.00$56,776$9,798.13+$209253913157569118208.00MSURGW

SURGW vs MRK: Complete Analysis 2026

SURGWStock

SurgePays, Inc. operates as a technology and telecommunications company. It offers mobile broadband services to consumers. The company's fintech platform utilizes a suite of financial and prepaid products to convert corner stores and bodegas into tech-hubs for underbanked neighborhoods. The company also provides ShockWave, an end-to-end cloud-based Software as a Service offering an Omnichannel customer relationship management, billing system, and carrier integrations to the telecommunication and broadband industry. In addition, the company provides Surge Blockchain software, a back-office marketplace offering wholesale consumable goods direct to convenience stores who are transacting on the SurgePays Fintech platform. Further, it offers lead generation and case management solutions primarily to law firms in the mass tort industry. The company was incorporated in 2006 and is headquartered in Bartlett, Tennessee.

Full SURGW Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this SURGW vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SURGW vs SCHDSURGW vs JEPISURGW vs OSURGW vs KOSURGW vs MAINSURGW vs JNJSURGW vs ABBVSURGW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.